- Home
- MYNZ vs INTS Comparison
MYNZ vs INTS Comparison
Compare MYNZ & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- INTS
- Stock Information
- Founded
- MYNZ 2021
- INTS 2012
- Country
- MYNZ Germany
- INTS United States
- Employees
- MYNZ N/A
- INTS N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- INTS Health Care
- Exchange
- MYNZ Nasdaq
- INTS Nasdaq
- Market Cap
- MYNZ 7.9M
- INTS 8.4M
- IPO Year
- MYNZ 2021
- INTS 2023
- Fundamental
- Price
- MYNZ $1.63
- INTS $0.29
- Analyst Decision
- MYNZ Buy
- INTS Strong Buy
- Analyst Count
- MYNZ 2
- INTS 4
- Target Price
- MYNZ $14.00
- INTS $4.50
- AVG Volume (30 Days)
- MYNZ 107.2K
- INTS 3.8M
- Earning Date
- MYNZ 10-21-2025
- INTS 08-07-2025
- Dividend Yield
- MYNZ N/A
- INTS N/A
- EPS Growth
- MYNZ N/A
- INTS N/A
- EPS
- MYNZ N/A
- INTS N/A
- Revenue
- MYNZ $893,991.00
- INTS N/A
- Revenue This Year
- MYNZ $26.06
- INTS N/A
- Revenue Next Year
- MYNZ $4.97
- INTS N/A
- P/E Ratio
- MYNZ N/A
- INTS N/A
- Revenue Growth
- MYNZ N/A
- INTS N/A
- 52 Week Low
- MYNZ $1.30
- INTS $0.19
- 52 Week High
- MYNZ $16.04
- INTS $4.34
- Technical
- Relative Strength Index (RSI)
- MYNZ 45.49
- INTS 47.38
- Support Level
- MYNZ $1.70
- INTS $0.27
- Resistance Level
- MYNZ $1.79
- INTS $0.32
- Average True Range (ATR)
- MYNZ 0.11
- INTS 0.02
- MACD
- MYNZ -0.00
- INTS 0.00
- Stochastic Oscillator
- MYNZ 14.06
- INTS 39.31
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.